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Abstract
Background: The main processing pathway for MHC class I ligands involves degradation of
proteins by the proteasome, followed by transport of products by the transporter associated with
antigen processing (TAP) to the endoplasmic reticulum (ER), where peptides are bound by MHC
class I molecules, and then presented on the cell surface by MHCs. The whole process is modeled
here using an integrated approach, which we call EpiJen. EpiJen is based on quantitative matrices,
derived by the additive method, and applied successively to select epitopes. EpiJen is available free
online.
Results: To identify epitopes, a source protein is passed through four steps: proteasome cleavage,
TAP transport, MHC binding and epitope selection. At each stage, different proportions of non-
epitopes are eliminated. The final set of peptides represents no more than 5% of the whole protein
sequence and will contain 85% of the true epitopes, as indicated by external validation. Compared
to other integrated methods (NetCTL, WAPP and SMM), EpiJen performs best, predicting 61 of
the 99 HIV epitopes used in this study.
Conclusion: EpiJen is a reliable multi-step algorithm for T cell epitope prediction, which belongs
to the next generation of in silico T cell epitope identification methods. These methods aim to
reduce subsequent experimental work by improving the success rate of epitope prediction.
Background
The accurate identification of T-cell epitopes remains a
critical step in the development of subunit and peptide-
based vaccines [1]. The first step of such studies is usually
in silico prediction of potential MHC binders from the
sequence of a studied protein, followed by labor-, time-
and resource-consuming experiments which aim to verify
the natural processing, presentation and T-cell recogni-
tion of the predicted peptides. As the veracity of initial in
silico predictions improves, so subsequent "wet lab" work
becomes faster, more efficient, and, ultimately, more suc-
cessful.
The main processing pathway for Major Histocompatibil-
ity Complex (MHC) class I ligands involves degradation
of proteins by the proteasome, followed by transport of
the products by the transporter associated with antigen
processing (TAP) to the endoplasmic reticulum (ER),
where peptides are bound to MHC class I molecules, and
then presented on the cell surface by MHCs. The proteas-
ome is responsible for generating the C terminus but not
the N terminus of the final presented peptide [2-5]. The
proteasome is a multimeric proteinase with three active
sites: a site with trypsin-like activity (cleavage after basic
residues), one with chymotrypsin-like activity (cleavage
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after hydrophobic residues), and another with pepti-
dylglutamyl-peptide hydrolytic activity (cleavage after
acidic residues) [6-8]. In addition, in vertebrates there are
three γ-interferon-inducible subunits that replace the con-
stitutive subunits [9] and assemble the immunoproteas-
ome. The immunoproteasomes have an altered hierarchy
of proteosomal cleavage, enhancing cleavage after basic
and hydrophobic residues and inhibiting cleavage after
acidic residues [10,11]. This is in accord with the amino
acid preferences for binding to MHC class I molecules at
the C terminus [12].
TAP is an ATP-dependent peptide transport protein that
belongs to the ATP-binding cassette (ABC) family of trans-
porters. This family transports across membranes a wide
range of molecules, from small sugars to large polypep-
tides [13]. There are two TAP proteins (TAP-1 and TAP-2)
which form a transmembrane (TM) heterodimer. Both
proteins encode one hydrophobic TM domain and one
ATP-binding domain [14]. Extant experimental studies
have shown that TAP prefers peptides of eight or more
amino acids with hydrophobic or basic residues at the car-
boxy terminus [15,16]. TAP-mediated antigen presenta-
tion is important not only for cytosolic antigens but also
for most epitopes within membrane/secretory proteins
[17]. The TAP-dependent pathway is the principal
processing route for peptides binding HLA-A1, HLA-A3,
HLA-A11, HLA-A24, HLA-B15 and HLA-B27 [18-20].
Some peptides are able to access the ER via other, TAP-
independent mechanisms. Examples of alleles exhibiting
only partial dependence on TAP include HLA-A2, HLA-
A23, HLA-B7 and HLA-B8 [21-24].
Proteins of the MHC are both polygenic (i.e. there are
more than one MHC class I and MHC class II genes) and
polymorphic (i.e. there are many alleles of each gene)
[25]. Each class of MHC has several loci: HLA-A, HLA-B
and HLA-C for class I and HLA-DR, HLA-DQ and HLA-DP
for class II. MHC alleles may differ by as many as 30
amino acid substitutions, most of them are found within
the binding site and are critical for the specificity of pep-
tide binding and therefore for T cell recognition [26-28].
Such an uncommon degree of polymorphism implies a
selective pressure to create and maintain it. Different pol-
ymorphic MHC alleles have different peptide specificities:
each allele binds peptides exhibiting particular sequence
patterns.
Successful T cell epitope prediction has always challenged
bioinformatics. A wide range of computer-based algo-
rithms have been developed to predict T-cell epitopes [29-
31]. Initially, methods for direct T cell epitope prediction
were developed based on amphipathicy [32], epitope pat-
tern motifs [33], or on a combination there of [34]. These
direct epitope prediction methods have relatively low
accuracy [35]. Later, a broad spectrum of indirect predic-
tive methods have been developed to predict MHC bind-
ers instead of T cell epitopes [reviewed in ref. [36]]. They
are based on motif patterns [37,38], motif profiles
[39,40], quantitative matrices (QM) [41-43], neural net-
works (ANN) [44-47], free energy scoring functions
(Fresno) [48], MHC-peptide threading [49], 3D-QSAR
studies [50-52] and support vector machines (SVM)
[53,54]. In general, methods of this type have out-per-
formed older methods. In the meantime, methods for the
prediction of proteasome cleavage [55-57] and TAP bind-
ing [58-61] were developed. These methods attempt to
model the early stages of the antigen processing pathway.
The next generation of T cell epitope identification meth-
ods will focus on integrated multi-step approaches, which
subsume proteasome cleavage, TAP transport and MHC
binding. The advantages of such integrated methods are
higher accuracy and a lower rate of false positive predic-
tions, although they may generate more false negative pre-
dictions due to the use of incomplete training sets or high
thresholds for individual steps. Although some previous
attempts have been made to combine predictive methods
[57,60,62,63], true integrated methods have only recently
emerged, examples include: SMM [64], NetCTL [65] and
WAPP [66]. SMM stands for Stabilized Matrix Method and
is a T cell epitope predictive tool based on QMs for bind-
ing to MHC class I molecules, peptide transport by TAP
and proteasomal (or immunoproteasomal) cleavage of
protein sequences [64]. NetCTL implements, in a com-
bined manner, ANN-based proteasome cleavage predic-
tion, a TAP binding QM and ANN-based MHC class I
binding prediction [65]. WAPP applies proteasomal cleav-
age matrices, SVM-based TAP and MHC predictions as a
series of successive filters [66]. All three methods empha-
size the greatly reduced number of peptides which need to
be tested in order to identify true epitopes; they show
good accuracy for sets they have been tested with.
In the present study, we develop a multi-step algorithm
for T cell epitope prediction, which we call EpiJen. The
method is applied to a set of overlapping peptides gener-
ated from a whole protein sequence and acts as a series of
filters which successfully reduce the number of potential
epitopes (Figure 1). The final set of peptides needed to be
tested for epitopes rarely includes more than 5% of the
whole sequence. QMs for each step were developed using
the additive method [42]. Since its appearance in 2001,
this method has been applied to more than 2500 peptides
binding to several human and murine MHC class I and
class II proteins [67] and has been shown to be both reli-
able and highly predictive, allowing us to design
superbinders [68]. The method was also used to generate
QMs for TAP binding [69] and proteasome cleavage [70].
Recently, several new models have been developed forBMC Bioinformatics 2006, 7:131 http://www.biomedcentral.com/1471-2105/7/131
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peptide binding to human MHC alleles: HLA-A*24, HLA-
B*07, HLA-B*27, HLA-B*40, HLA-B*44, HLA-B*51 and
HLA-B*53 (unpublished results). Here, we combine all
additive method human models and make them publicly
available via the EpiJen server for T cell epitope prediction
[71]. The performance of EpiJen is tested using external
sets of known T cell epitopes and is compared with the
predictions made by SMM, NetCTL and WAPP methods.
Results
EpiJen step one: proteasome cleavage
The dataflow in EpiJen is shown in Figure 1. Initially, the
protein is chopped into overlapping decamers and proc-
essed by a proteasome cleavage QM. A previously derived
and tested p1p1' model, as described in the Methods sec-
tion below [70], is used. The model takes into account
only the contributions of the residues next to the cleavage
site: C-terminus and the next aa. Two thresholds, 0.0 and
0.1, can be used here. Threshold 0.0 is recommended for
alleles which prefer Phe or Trp at the C-terminus: HLA-
A*24, HLA-B*07, HLA-B*27, HLA-B*35, HLA-B*51 and
HLA-B*53. The epitopes for other alleles are predicted
accurately at a threshold of 0.1. This initial step has a pow-
erful filtering ability: between one half and two thirds of
the true negatives were eliminated by this step. The
"cleaved" peptides, present as nonamers, are then passed
to the next filter: the TAP binding QM.
Flowchart of EpiJen Figure 1
Flowchart of EpiJen.BMC Bioinformatics 2006, 7:131 http://www.biomedcentral.com/1471-2105/7/131
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EpiJen step two: TAP transport
The TAP binding QM also has been derived and tested
previously [69]. A threshold of 5.00 is recommended for
both fully and partially TAP-dependent alleles. Pro and
Asp at anchor position 2 has a strong negative effect on
TAP binding [69]. For that reason, a threshold of 3.0 is rec-
ommended for epitopes binding to HLA-B*07, HLA-
B*35, HLA-B*40, HLA-B*44, HLA-B*51 and HLA-B*53.
The filtering ability of the TAP step is low. Up to 10% of
the true negatives are eliminated here. The "transported"
peptides move to the next filter: MHC binding.
EpiJen step three: MHC binding
EpiJen includes 18 QMs which can be used to predict
binding to different HLA-A and B alleles. Certain QMs
were developed for single alleles and others developed for
allele families. QMs developed for whole supertypes were
poorly predictive, especially for HLA-B supertypes. Some
MHC models were derived previously [42,52,72], while
others were developed for this study. The statistics of
newly derived models are given in Tables 1 and 2. Quan-
titative data (continuous values like IC50s) were available
for certain alleles, for the rest only sequences of binders
were known (discontinuous values). As is described in the
Methods section below, binding models based on contin-
uous values were derived by multiple linear regression
(MLR) (Table 1) and those based on discontinuous values
by discriminant analysis (DA) (Table 2). "Leave-one-out"
cross-validation tests indicate a higher predictive rate for
the DA models (AUCROC > 0.9; accuracy > 80%) than MLR
models (q2 ≈ 0.5). The filtering ability of this step is signif-
icant: approximately 25–30% of the true negatives are
eliminated here. The thresholds for this step are 0.5 for the
DA models and 5.3 for MLR models. These thresholds can
not be altered by the user. They seek to reduce the number
of false positives in long protein sequences.
EpiJen step four: epitope selection
All peptides which are presented by MHCs on the cell sur-
face after being cleaved by the proteasome and trans-
ported by TAP could potentially be T cell epitopes.
However, only a small number of all possible epitopes are
actually immunogenic. To reduce the number of false pos-
itives we tested different thresholds, which we defined as
percentages of available peptides sourced by one protein.
The top 5% threshold performed best, giving 85% sensi-
tivity; we recommend it and use it as a default value for
this step. Optional are thresholds 2, 3 and 4%.
External validation
A set of 160 epitopes and their source proteins were col-
lected from AntiJen [73]. They were restricted by the
human MHC allele families: HLA-A*01, HLA-A*02, HLA-
A*03, HLA-A*11, HLA-A*24, HLA-A*33, HLA-A*68,
HLA-B*07, HLA-B*27, HLA-B*35, HLA-B*40, HLA-B*44,
HLA-B*51 and HLA-B*53. Six epitopes were promiscu-
ous. Only proteins consisting of less than 1000 amino
acids were used in the study. The thresholds were selected
as follows: at step 1 (proteasome cleavage) a value of 0.0
was chosen for HLA-A*24, HLA-B*07, HLA-B*27, HLA-
B*35, HLA-B*51 and HLA-B*53, and 0.1 for the rest; at
step 2 (TAP transport) a value of 3.0 for HLA-B*07, HLA-
B*35, HLA-B*51 and HLA-B*53, and 5.0 for the rest; at
step 3 (MHC binding) a value of 0.5 was selected for HLA-
A*24, HLA-B*27, HLA-B*40 and HLA-B*44, and 5.3 for
the rest. For the final step (epitope selection) four thresh-
olds were tested: top 2% to 5%. As the number of non-
epitopes generated from each protein was significantly
higher than the number of epitopes, only two parameters
– sensitivity ((true positives/(true positives + false nega-
tives)) and positive predictive value (PPV) ((true positives/
(true positives + false positives)) – were used for compar-
ison. Parameters accuracy  ((true positives + true nega-
Table 2: Statistics of the MHC models (EpiJen step 3), derived in this study by DA-PLS.
Model binders non-binders non-binders after HC selection "leave-one-out" cross-validation
AUCROC accuracy at threshold 0.5
HLA-A*24 binding 72 2109 67 0.949 0.885
HLA-B*27 binding 68 877 61 0.988 0.899
HLA-B*40 & B*44 binding 20+19 619+555 19+18 0.916 0.842
Table 1: Statistics of the MHC models (EpiJen step 3), derived in this study by MLR-PLS.
Model n q2 PC SEP r2 SEE F-ratio
HLA-B*07 binding 77 0.536 6 0.750 0.980 0.156 567.597
HLA-B*51 binding 69 0.495 4 0.775 0.959 0.221 371.878
HLA-B*53 binding 55 0.439 5 0.898 0.972 0.200 342.130BMC Bioinformatics 2006, 7:131 http://www.biomedcentral.com/1471-2105/7/131
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tives)/total) and specificity ((true negatives/(true negatives
+ false positives)) could be misleading. If 98% of the pep-
tides in one source protein are non-epitopes, a model that
simply predicts everything as non-epitope will not be very
useful, yet it will nonetheless have an overall accuracy of
98% and a specificity of 100%.
The true positives were 141 (5% cutoff), 132 (4% cutoff),
123 (3% cutoff) and 114 (2% cutoff). False negatives were
25, 34, 43 and 52, while the false positives decreased from
2743 to 2173, 1618 and 1060, respectively. The parameter
sensitivity varies from 69% (at 2% cutoff) to 85% (at 5%
cutoff) (Figure 2). The parameter PPV diminishes from
10% (at 2% cutoff) to 5% (at 5% cutoff). Thus, our tests
indicate that a 5% threshold at the final epitope selection
step is sufficient to generate an 85% epitope prediction.
This means that by using EpiJen, one need only test 5% of
the whole sequence in order to predict 85% of available
epitopes. Detailed results from the external validation are
given in Additional File 1, which is provided as Additional
Material.
Comparison with SMM, NetCTL and WAPP
The ability of EpiJen to predict T cell epitopes was tested
on a set of known T cell epitopes, which belonged to 12
HIV proteins, and the resulting predictions were com-
pared with those made by SMM, NetCTL and WAPP. The
comparisons were made in conditions close to those used
by experimental immunologist: the complete sequence of
a protein of interest is submitted to an available web
server and the results recorded. NetCTL and WAPP predic-
tions were made using default thresholds. The top 5% best
predicted peptides were selected as a threshold for SMM
and EpiJen. As WAPP only predicts peptides binding only
to HLA-A*01, HLA-A*02, HLA-A*03 and HLA-B*27, but
SMM does not predict HLA-B*27 binding, the epitopes
used in the test set were restricted to the set of alleles com-
mon to all four programs: HLA-A*01, HLA-A*02 and
HLA-A*03. As described in Methods, a set of 99 epitopes
was compiled: 4 peptides binding to HLA-A*01, 66 to
HLA-A*02 and 29 to HLA-A*03. Three peptides were pro-
miscuous, binding to both HLA-A*02 and HLA-A*03. The
predictions were compared in terms of sensitivity and PPV.
EpiJen recognized 61 out of 99 epitopes (62%sensitivity),
followed by SMM with 57 (58%sensitivity), NetCTL with
49 (50%sensitivity), and WAPP with 33 (33%sensitivity)
(Table 3). The PPVs were low for all of the four methods:
21% for NetCTL, 17% for both EpiJen and WAPP, and
16% for SMM. Detailed results from this comparative
study are given in Additional File 2, which is provided as
Additional Material.
Discussion
EpiJen is a server for multistep T cell epitope prediction.
The principal steps in the antigen processing pathway are
modeled by a set of different QMs. The models are applied
successively, eliminating a proportion of negatives at each
stage. Proteasome cleavage (step 1) and TAP transport
(step 2) models are applied to all alleles. MHC binding
(step 3) is more specific. Several models are included here.
Some, like HLA-A*0101, HLA-A*0201, HLA-A*0202,
HLA-A*0203, HLA-A*0206, HLA-A*0301, HLA-A*1101,
HLA-A*3101, HLA-A*6801, HLA-A*6901 and HLA-
A*3501, relate to single alleles. Others, such as HLA-
A*24, HLA-B*07, HLA-B*27, HLA-B*40, HLA-B*44,
HLA-B*51 and HLA-B*53, are valid for whole allele fam-
ilies. The final epitope selection step (step 4) reduces the
number of false positives by selecting the top 5 to 2% of
the best binders.
EpiJen combines several widely used methods in drug
design [74,75], which have generally proven reliable and
predictive. Moreover, the external validation of EpiJen
and the comparison with other integrated methods
showed that EpiJen performed best in terms of sensitivity.
The number of peptides that have to be tested in order to
reach 85% reliability is 5% of a protein sequence. Accord-
ing to Larsen et al. [65], NetCTL, SYFPEITHI and BIMAS
achieve 85% reliability within the top 7%, 10% and 9%,
respectively. The moderate performance of all integrated
methods when used to predict the HIV epitope set may be
due to the fact that all peptides available in the Los Ala-
mos HIV Database were included, regardless of whether a
peptide has been naturally processed or not. EpiJen
excluded most of the false negative HIV epitopes after the
proteasome cleavage step and only a few of them were
predicted as nonbinders.
External validation of EpiJen Figure 2
External validation of EpiJen. Sensitivity (--) and PPV (-▲-) 
are given at different thresholds.BMC Bioinformatics 2006, 7:131 http://www.biomedcentral.com/1471-2105/7/131
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It is well known that "all models are wrong, yet some of
them might be useful". The modeling process follows the
accumulation of knowledge about a particular mecha-
nism. As knowledge improves, so models improve. Anti-
gen processing is a very complicated cascade of cellular
events. It is clear that, for example, cleavage by the protea-
some is only one event in antigen presentation: there are
many more, and many of these are proteolytic. Analyses
of peptide generation and T-cell epitopes expression in
proteasome-inhibited cells suggest that cytoplasmic pro-
teases other than proteasomes may also be involved in
antigen processing pathway [76-78]. Tripeptidylpeptidase
II (TPPII) was suggested to supply peptides because of its
ability to cleave peptides in vitro and its upregulation in
cells surviving partial proteasome inhibition [79]. Leucine
aminopeptidase was found to generate antigenic peptides
from N-terminally extended precursors [80]. Puromycin
sensitive animopeptidase and bleomycin hydrolase were
shown to trim N termini of synthetic peptides [81]. An
enzyme located in the lumen in ER and called ERAAP (ER
aminopeptidase associated with antigen processing) [82]
or ERAP1 (ER aminopeptidase 1) [83,84], has been
shown to be responsible for the final trimming of the N
termini of peptides presented by MHC class I molecules.
Recently, it was shown that within the proteasome, pep-
tides could be formed from noncontiguous parts of the
source protein [85,86]. The mechanism of this splicing is
not fully understood. Currently there is insufficient quan-
titative data about the role of the above mentioned events
to allow a precise bioinformatic evaluation of their impact
on the antigen processing pathway. Overall, it is clear that,
ultimately, many more pathways, involving many more
stages, will need to incorporated into predictive methods
in order to model it accurately; given current data, how-
ever, EpiJen represents the most accurate and parsimoni-
ous approach to antigen prediction.
Compared to other methods, EpiJen offers many potential
advantages. First, a large quantity of experimental data
(more than 2500 peptides) has been used to develop the
models. Second, the additive method combines two well
known, widely used methods in drug design [42], which
have generally proven to be both reliable and predictive:
the Free-Wilson method [74] and partial least squares
(PLS) [75]. Finally, and most importantly, EpiJen uses its
models as successive filters: negatives are eliminated at
each step rather than their score being summed in order
to exceed a global threshold. This is in contrast to alterna-
tive methods [64,65]. The combined score, as used by
SMM and NetCTL, obscures the final result, because a low
Table 3: Comparison between EpiJen, NetCTL, WAPP and SMM on HIV epitopes, binding to HLA-A*01, HLA-A*02 and HLA-A*03.
p17 p24 protease RT integrase rev tat vif vpr vpu gp160 nef total
A*01 1 0 0 0 0 1 0 0 0 0 1 1 4
A*02 2 9 2 11 3 3 0 3 4 1 20 8 66
A*03 2 2 1 9 2 2 1 2 0 0 4 4 29
total 5 11 3 20 5 6 1 5 4 1 25 13 99
EpiJen
TP 5 7 2 14 2 5 1 3 2 0 14 6 61
FN 0 4 1 6 3 1 0 2 2 1 11 7 38
FP 16 17 8 42 26 13 4 17 3 4 115 24 289
Sensitivity % 100 64 67 70 40 83 100 60 50 0 56 46 62
PPV % 24 29 20 25 7 28 20 15 40 0 11 20 17
NetCTL
TP 4 6 1 10 3 3 1 4 1 0 12 4 49
FN 1 5 2 10 2 3 0 1 3 1 13 9 50
FP 8 10 6 39 22 5 7 11 4 2 60 14 188
Sensitivity %8 0 5 5 3 3 5 0 6 0 5 0 1 0 0 8 0 2 5 0 4 83 1 50
PPV %3 3 3 81 4 2 01 23 8 1 3 2 7 2 0 0 1 7 2 2 21
WAPP
TP 2 2 2 7 1 4 0 3 3 0 8 1 33
FN 3 9 1 13 4 2 1 2 1 1 17 12 66
FP 8 6 4 40 13 6 2 13 0 6 61 7 166
Sensitivity %4 0 1 8 6 7 3 5 2 0 6 7 0 6 0 7 5 0 3 2 833
PPV %2 0 2 53 3 1 574 0 0 1 9 1 0 0 0 1 2 1 3 17
SMM
TP 3 6 2 15 5 4 0 3 2 0 14 3 57
FN 2 5 1 5 0 2 1 2 2 1 11 10 42
FP 15 18 8 41 23 14 5 17 3 4 115 27 290
Sensitivity % 60 55 67 75 100 67 0 60 50 0 56 23 58
PPV %1 7 2 52 0 2 71 82 2 0 1 5 4 0 0 1 1 1 0 16BMC Bioinformatics 2006, 7:131 http://www.biomedcentral.com/1471-2105/7/131
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(or even negative) TAP and/or proteasome score could be
compensated for by a high MHC score. The cellular anti-
gen processing pathway, as modeled in EpiJen, works in a
hierarchical or successive manner not in parallel. Peptides
that have been eliminated at any of the steps do not con-
tinue to the next step. EpiJen is thus based on a more
mechanistically meaningful model of antigen presenta-
tion than other available methods. EpiJen is both a more
adaptable and a more flexible approach, which should
prove a significant advantage as combination methods,
such as this, evolve.
Conclusion
EpiJen belongs to a new generation of integrated methods
for T cell epitope prediction. It is an open system: new
models will be included in the future, while old ones will
be improved. Integrated methods aim to rationalize the
process of epitope searching and accelerate epitope-based
vaccine design. They possess significant potential for
improving the predictive ability of in silico epitope identi-
fication by adding more features and new high quality
experimental data.
Methods
Peptide datasets
More than 2500 peptides (nonamers) were used to
develop models involved in EpiJen. Models for proteas-
ome cleavage [70], TAP binding [69], HLA-A2 [71], HLA-
A3 [52] and HLA-B35 [87] binding were derived previ-
ously. The majority of peptides were extracted from Anti-
Jen [73], although the SYFPEITHI database [38] was also
used. As has been described elsewhere [70], the training
set for the proteasome cleavage model consisted of 489
naturally processed T-cell epitopes associated with HLA-A
and HLA-B molecules and a test set of 231 peptides were
used for external validation. All T-cell epitopes common
to the two sets were first excluded from the training set.
The training set for the TAP binding model included 163
poly-Alanine nonameric peptides and two test sets con-
taining 85 peptides were used for external validation [69].
1371 peptides were used for the development of the MHC
binding models; the models were tested by "leave-one-
out" cross-validation (LOO-CV).
Additive method
The additive method [42] can be used to develop a QM for
any particular peptide-protein interaction. Nonameric
peptides are presented as a binary string of length 180 (9
positions × 20 amino acids). A term is equal to 1 when a
particular amino acid at a particular position is present
and 0 when it is absent. The dependent variable could
take either continuous values, like logIC50, or discontinu-
ous ones, such as binder or non-binder. When the
dependent variable is continuous, multiple linear regres-
sion is used to derive the QM. In the case of a discontinu-
ous dependent variable, models are derived by
discriminant analysis. In both cases, the matrix is solved
using partial least squares (PLS).
Partial least squares (PLS)
PLS is a so called projection method [75], which can han-
dle matrices with more variables than observations and
with noisy and highly collinear data. In such cases, con-
ventional statistical methods, such as multiple linear
regression, produce over-fitted models, i.e. models that fit
the training data well but are unreliable in prediction. PLS
forms new variables, or principal components (PC), as
linear combinations of the initial variables and then uses
them to predict the dependent variable. The PLS method
used in this study was implemented in SYBYL 6.9 [88].
The type of the dependent variable (continuous or discon-
tinuous) determined the statistical method: linear regres-
sion or discriminant analysis.
Multiple linear regression by partial least squares (MLR-
PLS)
MLR-PLS requires at least 30 peptides with experimentally
measured affinities (IC50) to generate good models. In
this study MLR was applied only to models for binding to
HLA-B7, HLA-B51 and HLA-B53 alleles. IC50 values were
collected from AntiJen [73]. The optimal number of PC
used to derive the model was defined as the number
which lead to the highest cross-validated q2 and/or the
lowest standard error of prediction (SEP). The q2 values
were derived after "leave-one-out" cross-validation (LOO-
CV). The non-cross-validated models were assessed by the
explained variance r2, standard error of estimate (SEE),
and F-ratio. The non-cross-validated models were used at
EpiJen step 3.
Discriminant analysis by partial least squares (DA-PLS)
Not enough quantitative data was found for peptide bind-
ing to alleles HLA-A24, HLA-B27, HLA-B40 and HLA-B44.
Instead, sets of MHC binders for each allele were collected
from AntiJen and SYFPEITHI. Each source protein was
passed through the first two steps of EpiJen (proteasome
cleavage and TAP binding) and only properly "cleaved"
and "TAP-transported" peptides were selected. Among
them the binders form a small set; the rest were consid-
ered as non-binders. The number of non-binders was sig-
nificantly higher than that of binders (Table 2). In order
to develop a reasonable model by DA, equivalent num-
bers of binders and non-binders are required. Otherwise,
a model will represent an over- or under- estimation of
amino acids contributions. The number of non-binders
was reduced by the method of hierarchical clustering, as
described below. This resulted in almost equivalent num-
bers of binders and non-binders for each allele family. The
QMs were derived by PLS. The optimum number of PCs
used do derive the model was defined as the number lead-BMC Bioinformatics 2006, 7:131 http://www.biomedcentral.com/1471-2105/7/131
Page 8 of 11
(page number not for citation purposes)
ing to the lowest standard error of prediction (SEP) after
"leave-one-out" cross-validation (LOO-CV). The predic-
tion rate of the models was measured by LOO-CV using
Receiver Operating Characteristic (ROC) curves [89]. Two
variables sensitivity (true positives/total positives) and 1-
specificity (false positives/total negatives) were calculated
at different thresholds. The area under the curve (AUCROC)
is a quantitative measure of predictive ability and varies
from 0.5 for a random prediction to 1.0 for a perfect pre-
diction. Prediction a ccuracy ((true positives + true nega-
tives)/total) at a threshold 0.5, was also calculated. The
non-cross-validated models were used at EpiJen step 3.
Hierarchical clustering (HC)
Clustering is the process of dividing a set of entities into
several subsets. Members of each subset are similar to each
other but different from members of other subsets [90].
There have been numerous cluster methods described
[91]. In the present study, HC, using the agglomerative
algorithm [90], was applied. According to this algorithm,
clusters are built from the bottom up, first by merging
individual items into clusters, and then by merging clus-
ters into superclusters, until the final merge brings all
items into a single cluster. This method was applied as
implemented in Sybyl 6.9 [88]. The distance between the
clusters was calculated using the complete-linkage
method, i.e. the distance between the most distant pair of
data points in both clusters is taken into account.
In this study, HC reduced the number of non-binders for
the DA-PLS models, i.e. models for peptide binding to
HLA-A24, HLA-B27, HLA-B40 and HLA-B44. The last sec-
ond or third level of the dendrogram, which contained a
number of clusters close to the number of binders, was
used. One peptide from each cluster was chosen at ran-
dom to act as the exemplar for that cluster.
Test sets
For the external validation of EpiJen, a set of 160 epitopes,
and their source proteins were collected from AntiJen. The
epitopes were not been used to develop any of the models
included in EpiJen. Six epitopes were restricted to HLA-
A*01, 58 to HLA-A*02, 4 to HLA-A*03, 6 to HLA-A*11,
25 to HLA-A*24, 1 to HLA-A*33, 1 to HLA-A*68, 12 to
HLA-B*07, 10 to HLA-B*27, 25 to HLA-B*35, 1 to HLA-
B*40, 7 to HLA-B*44, 6 to HLA-B*51 and 4 to HLA-B*53.
To reduce the number of non-epitopes, only proteins con-
sisting of less than 1000 amino acids were considered in
the study. As the number of non-epitopes generated from
one protein was significantly higher than the number of
epitopes, only two parameters – sensitivity and positive pre-
dictive value ((true positives/(true positives + false posi-
tives)) – were used for the assessment of program
performance.
For the comparison between the integrated methods, a set
of known HIV epitopes was collected from the CTL/CD8+
T cell epitope maps published in the HIV Molecular
Immunology Database (last updates June 8, 2005) of the
Los Alamos National Laboratory [92]. Epitopes are
mapped to the HXB2 consensus protein sequence. Only
nonamer epitopes, restricted by HLA-A*01, HLA-A*02
and HLA-A*03 at the serotype level, were included in the
test set. Epitopes which spanned a protein boundary were
not considered. The final set consisted of 99 epitopes from
12 source proteins. Proteins p2p7p1p6 and gag/pol TF did
not have epitopes of interest and were not used. Four
epitopes were restricted by HLA-A*01, 66 – by HLA-A*02
and 29 – by HLA-A*03. Three of the epitopes were pro-
miscuous. Parameters sensitivity and positive predictive value
were used to assess the results.
EpiJen Server
The EpiJen server is implemented in Perl, with an interface
written in HTML. EpiJen identifies epitopes from nucleic
acid and protein sequences, using the four-stage model
described above, with options to vary the relevant requi-
site parameters, such as selected MHC allele and individ-
ual model thresholds. Prediction from nucleic acid allows
for 3 or 6 frame translation, as recently it has become
known that many antigenic peptides emerge from cryptic
translational reading frames [93,94], as well as through
post-translational splicing [85,86], amongst other non-
canonical expression mechanisms.
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